Promotional price valid on web orders only. Your contract pricing may differ. Interested in signing up for a dedicated account number?
Learn More
Learn More
CERILLIANT™ Lacosamide-13C, D3 Solution, 100 μg/mL in Acetonitrile, Sold by MilliporeSigma™ Supelco™
Certified reference material
Supplier: MilliporeSigma Supelco L0271ML
Description
Lacosamide is a new antiepileptic drug approved by the FDA in late 2008 for the treatment of partial-onset seizures and diabetic neuropathic pain. The drug is marketed under the trade name Vimpat™. This internal standard is suitable for lacosamide testing methods by LC/MS or GC/MS for clinical toxicology, forensic analysis, or urine drug testing.
Specifications
| 75-05-8 | |
| UN 1648 3 / PGII | |
| 254.30 | |
| 1 mL |
| 13CC12D3H15N2O3 | |
| 100 μg/mL in acetonitrile | |
| Ampule | |
| 2°C (35.6°F) - closed cup |
Safety and Handling
H332-H319
H312
EINECSNumber : 200-835-2
Recommended Storage : -20°C
Product Title
By clicking Submit, you acknowledge that you may be contacted by Fisher Scientific in regards to the feedback you have provided in this form. We will not share your information for any other purposes. All contact information provided shall also be maintained in accordance with our Privacy Policy.
Spot an opportunity for improvement?
CERILLIANT is a registered trademark of Cerilliant Corporation